We are live on ! Find out more
CRBU icon

Caribou Biosciences

126 hedge funds and large institutions have $338M invested in Caribou Biosciences in 2023 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 58 increasing their positions, 19 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

205% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 19

82% more capital invested

Capital invested by funds: $185M → $338M (+$153M)

69% more call options, than puts

Call options by funds: $616K | Put options by funds: $364K

33% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 21

8.87% more ownership

Funds ownership: 71.3%80.17% (+8.9%)

4% more funds holding

Funds holding: 121126 (+5)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
126
Holders Change
+5
Holders Change %
+4.13%
% of All Funds
2%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
28
Increased
58
Reduced
19
Closed
21
Calls
$616K
Puts
$364K
Net Calls
+$252K
Net Calls Change
+$247K
Name Holding Trade Value Shares
Change
Change in
Stake
PHS
1
PFM Health Sciences
California
$32.1M +$7.16M +1,153,846 +21%
BlackRock
2
BlackRock
New York
$29.1M +$8.19M +1,319,831 +28%
APM
3
Avidity Partners Management
Texas
$28.9M +$20.4M +3,291,612 +119%
State Street
4
State Street
Massachusetts
$25.6M +$26.6M +4,283,243 +400%
Vanguard Group
5
Vanguard Group
Pennsylvania
$18.3M +$7.83M +1,261,920 +49%
DM
6
Deerfield Management
New York
$16.7M +$21.7M +3,500,000 New
Point72 Asset Management
7
Point72 Asset Management
Connecticut
$16.7M +$19.9M +3,210,094 +1,108%
PBA
8
Paradigm Biocapital Advisors
New York
$14.1M +$18.3M +2,944,513 New
RCMU
9
Rokos Capital Management (UK)
United Kingdom
$13.3M
Assenagon Asset Management
10
Assenagon Asset Management
Luxembourg
$12.7M +$11.7M +1,886,484 +248%
EWM
11
Elmwood Wealth Management
California
$11.3M
Bank of America
12
Bank of America
North Carolina
$11M -$2.76M -444,692 -16%
Pictet Asset Management
13
Pictet Asset Management
Switzerland
$9.22M +$12M +1,929,389 New
Morgan Stanley
14
Morgan Stanley
New York
$8.69M +$3.42M +550,946 +43%
Alkeon Capital Management
15
Alkeon Capital Management
New York
$7.86M +$1.79M +287,800 +21%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$7.54M +$2.89M +465,590 +42%
Fidelity Investments
17
Fidelity Investments
Massachusetts
$6.91M +$12.5K +2,007 +0.1%
KCM
18
Kynam Capital Management
New Jersey
$5.11M +$6.63M +1,068,527 New
SCM
19
Silverarc Capital Management
Massachusetts
$4.27M +$5.54M +892,786 New
Fidelity International
20
Fidelity International
Bermuda
$4.11M
Northern Trust
21
Northern Trust
Illinois
$3.28M +$963K +155,181 +29%
MC
22
Maverick Capital
Texas
$3.12M
Dimensional Fund Advisors
23
Dimensional Fund Advisors
Texas
$2.84M +$2.87M +462,997 +354%
Charles Schwab
24
Charles Schwab
California
$2.83M +$1.11M +179,224 +43%
JP Morgan Chase
25
JP Morgan Chase
New York
$2.74M -$123K -19,804 -3%

CRBU Hedge Fund Activity: Q3 2023 in Review

126 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Caribou Biosciences (CRBU) for Q3 2023, worth a combined $338M — up 82% from $185M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new CRBU positions and 21 closed out — a net gain of 7 holders — while 58 added to existing stakes and 19 trimmed.

The largest buyer was State Street, adding an estimated $26.6M. The largest seller was Millennium Management, cutting an estimated $3.64M.

  • 126 institutional investors held Caribou Biosciences (CRBU) as of Q3 2023, up from 121 in Q2 2023.
  • Funds reported $338M of Caribou Biosciences stock for Q3 2023, up 82% quarter-over-quarter.
  • 28 funds opened new Caribou Biosciences positions in Q3 2023 and 21 closed out, a net change of +7 holders.
  • The largest Caribou Biosciences buyer in Q3 2023 was State Street, an estimated $26.6M added.
  • The largest Caribou Biosciences seller in Q3 2023 was Millennium Management, an estimated $3.64M sold.

Based on aggregated 13F filings for Q3 2023.